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Research
During the last decade research has revealed 
that conditions experienced during early 
development play an important role in deter-
mining the long-term health of individuals. 
Alterations in development due to impaired 
maternal metabolism can lead to the perma-
nent programming of physiological systems. 
Gestation generates a state of increased meta-
bolic demand to ensure a balance between 
maternal and fetal requirements. To meet the 
demands of pregnancy, a coordinated series of 
maternal adaptations occur, including changes 
of metabolic processing within different tis-
sues and changes in nutrient partitioning that 
ensure proper growth of the fetus (Ryan 2003). 
The most profound of these adaptations occurs 
with glucose metabolism because glucose is 
the primary nutrient for fetal growth and milk 
synthesis. Thus, glucose production increases 
during late pregnancy and early lactation, 
and concurrently, glucose uptake by muscle 
and adipose tissue progressively declines. This   
insulin-resistant state ensures that an adequate 
supply of glucose is shunted to the growing 
fetus (Barbour et al. 2007; King 2006). Despite 
this condition, serum glucose concentrations 
are maintained within the physio  logical range 
because the maternal endocrine pancreas 
adapts by increasing insulin secretion. If this 
adjustment fails, gestational diabetes ensues 
(Kuhl 1998). Experimental and epidemiologi-
cal data suggest that gestational diabetes may 
have long-term consequences for both baby 
and mother, including a predisposition to obe-
sity, metabolic syndrome, and diabetes later in 
life (Boloker et al. 2002; Reece et al. 2009).
In addition to insulin, other hormones 
change significantly in response to gestation. 
The rise of maternal serum levels of prolactin, 
placental lactogens, progesterone, and estradiol 
(E2) in late pregnancy is related, at least in 
part, to the development of insulin resistance 
(Gonzalez et al. 2003; Nadal et al. 2009b). 
Among these hormonal adaptations, those 
related to E2 are key. In addition to its role in 
the physiology of reproduction, E2 has been 
proposed to mediate maternal adaptation to 
the enhanced demand for insulin because it 
enhances insulin biosynthesis as well as glu-
cose-stimulated insulin secretion (Nadal et al. 
2009b). Although physiological levels of E2 
are involved in maintaining normal insulin 
sensitivity (Liu and Mauvais-Jarvis 2010; Louet 
et al. 2004), E2 outside of the physio  logical 
range may have adverse effects on glucose 
homeostasis (Livingstone and Collison 2002; 
Nadal et al. 2009a).
Recently, environmental estrogens such 
as bisphenol A (BPA) have become public 
health concerns because of experimental evi-
dence indicating deleterious effects on energy 
balance and glucose homeostasis in animal 
models (Alonso-Magdalena et al. 2006, 2008; 
Nadal et al. 2009a; Newbold et al. 2008). In 
humans, BPA has been associated epidemio-
logically with type 2 diabetes and heart disease 
(Lang et al. 2008). Although first discovered 
as a synthetic estrogen (Dodds and Lawson 
1936), BPA is currently used as the base com-
pound in the manufacture of polycarbonate 
plastic and the resin lining of food and beverage 
cans and drinking water bottles and containers 
(vom Saal et al. 2007). Importantly, BPA has 
been shown to leach from poly  carbonate con-
tainers, and consequently, BPA has been widely 
detected in humans. Indeed, the potential risk 
for BPA exposure is emphasized by the finding 
of Calafat et al. (2008) that BPA was present in 
92.6% of the urine samples from U.S. residents. 
The concentration of BPA in human serum 
ranges from 0.2 to 1.6 ng/mL (0.88–7.0 nM) 
(Vandenberg et al. 2007). In addition, it is has 
been detected in amniotic fluid, neonatal blood, 
placenta, cord blood, and human breast milk, 
demonstrating the potential of this compound 
to pass from mother to fetus (Vandenberg et al. 
2007). Many in vivo and in vitro studies have 
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Ba c k g r o u n d: Bisphenol A (BPA) is a widespread endocrine-disrupting chemical used as the base 
compound in the manufacture of polycarbonate plastics. In humans, epidemiological evidence has 
associated BPA exposure in adults with higher risk of type 2 diabetes and heart disease.
oB j e c t i v e: We examined the action of environmentally relevant doses of BPA on glucose metabo-
lism in mice during pregnancy and the impact of BPA exposure on these females later in life. We also 
investigated the consequences of in utero exposure to BPA on metabolic parameters and pancreatic 
function in offspring.
Me t h o d s : Pregnant mice were treated with either vehicle or BPA (10 or 100 µg/kg/day) during 
days 9–16 of gestation. Glucose metabolism experiments were performed on pregnant mice and 
their offspring.
re s u l t s: BPA exposure aggravated the insulin resistance produced during pregnancy and was 
associated with decreased glucose tolerance and increased plasma insulin, triglyceride, and leptin 
concentrations relative to controls. Insulin-stimulated Akt phosphorylation was reduced in skeletal 
muscle and liver of BPA-treated pregnant mice relative to controls. BPA exposure during gestation 
had long-term consequences for mothers: 4 months post  partum, treated females weighed more 
than untreated females and had higher plasma insulin, leptin, triglyceride, and glycerol levels and 
greater insulin resistance. At 6 months of age, male offspring exposed in utero had reduced glucose 
tolerance, increased insulin resistance, and altered blood parameters compared with offspring of 
untreated mothers. The islets of Langerhans from male offspring presented altered Ca2+ signaling 
and insulin secretion. BrdU (bromodeoxyuridine) incorporation into insulin-producing cells was 
reduced in the male progeny, yet β-cell mass was unchanged.
co n c l u s i o n s: Our findings suggest that BPA may contribute to metabolic disorders relevant to 
glucose homeostasis and that BPA may be a risk factor for diabetes.
key w o r d s : bisphenol A, diabetes, endocrine disruptors, estrogen, gestational diabetes, islet of 
Langerhans, pregnancy, xenoestrogens. Environ Health Perspect 118:1243–1250 (2010).  doi:10.1289/
ehp.1001993 [Online 19 May 2010]Alonso-Magdalena et al.
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reported adverse effects associated with BPA, 
and interestingly, many were caused by con-
centrations below the predicted “safe” refer-
ence dose of 50 µg/kg/day established by the 
U.S. Environmental Protection Agency (EPA) 
(vom Saal et al. 2007). In the present study, 
we chose low doses of BPA based on the U.S. 
EPA criterion for low-dose effects of endocrine- 
disrupting chemicals (EDCs). Levels below the 
current lowest observed effect level (LOAEL) 
of 50 mg/kg/day have been considered low 
dose for in vivo studies (Wetherill et al. 2007; 
U.S. EPA 2010). Although the initial concerns 
about BPA were related to reproductive param-
eters and its carcinogenic potential, few studies 
have examined the consequences of BPA expo-
sure during pregnancy on the mother, and no 
study has assessed the potential risk for devel-
oping diabetes, despite the fact that gestational 
diabetes is a major potential complication of 
pregnancy with adverse consequences for both 
mothers and newborns.
In the present study, we demonstrate that 
low concentrations of BPA have deleterious 
long-term effects on glucose metabolism in 
mice during pregnancy and post  partum, as 
well as in their adult offspring. Our results 
suggest that BPA exposure could contribute 
to the development of gestational diabetes, 
obesity, and a pre  diabetic state later in life. 
Notably, in utero exposure to BPA was asso-
ciated with decreased glucose tolerance and 
increased insulin resistance in male offspring 
at 6 months of age compared with controls, 
consistent with an effect of BPA on fetal pro-
gramming that could predispose adult mice to 
type 2 diabetes and metabolic disorders.
Materials and Methods
Animals and treatment. Pregnant OF-1 
mice (F0) were purchased from Charles River 
(Barcelona, Spain) and individually housed 
under standard housing conditions. Mice 
were maintained on 2014 Teklad Global 14% 
Protein Rodent Maintenance Diet (Harlan 
Laboratories, Barcelona, Spain), which does 
not contain alfalfa or soybean meal. The com-
position of the diet is as follows: crude protein, 
14.3%; fat, 4%; carbohydrate, 48%; crude 
fiber, 4.1%; neutral detergent fiber, 18%; ash, 
4.7%; energy density, 2.9 kcal/g (12.1 kJ/g); 
calories from protein, 20%; calories from fat, 
13%; and calories from carbohydrate, 67%. 
Experimental procedures were reviewed 
and approved by the institutional committee 
for animal care and use of the Universidad 
Miguel Hernández de Elche. Animals were 
treated humanely and with regard for allevia-
tion of suffering.
BPA was dissolved in tocopherol-stripped 
corn oil and administered subcutaneously on 
days 9–16 of gestation (GD9–GD16). The 
daily dose used was 10 or 100 µg/kg. We 
observed no significant difference in litter 
size between control and BPA-treated mice. 
Pups of the same treatment group were pooled 
together and then placed in equal numbers 
(11 pups/group) with foster mothers of the 
same treatment group; pups housed together 
were of the same sex. Pups were weighed on 
postnatal days 1, 3, 5, 8, 10, 12, 16, and 21. 
Mean body weight was calculated as the mean 
of individual body weight of each pup per 
group per day. Animals were weaned on post-
natal day 21 and housed (8 mice/group) from 
weaning through adulthood.
Glucose and insulin tolerance tests. For the 
intra  peritoneal glucose tolerance tests (IPGTT) 
animals were fasted overnight for 12 hr, and 
blood samples were obtained from the tail vein. 
Animals were then injected intra  peritoneally 
with glucose at 2 g/kg body weight, and blood 
samples were taken at the indicated intervals 
(0, 15, 30, 60, and 120 min). For the intra-
peritoneal insulin tolerance tests (IPITT), fed 
animals were injected intra  peritoneally with 
soluble insulin at 0.75 or 1.25 IU/kg body 
weight. Blood glucose was measured in each 
sample after 0, 15, 30, 45, and 60 min using 
an Accu-Chek compact glucometer (Roche, 
Madrid, Spain).
Plasma analysis. To measure plasma 
metabo  lites, mice were anesthetized with 
sodium pentobarbital at 50 mg/kg body weight. 
Blood was obtained by cardiac puncture. Insulin 
and leptin were measured by enzyme-linked 
immuno  sorbent assay (Mercodia, Uppsala, 
Sweden, and Crystal Chem, Downers Grove, 
IL, USA, respectively), and trigly  cerides and 
glycerol were measured with the GTO-Trinder 
Triglycerides assay (Sigma, Madrid, Spain).
Insulin secretion measurement. Pancreatic 
islets of Langerhans from 6-month-old F1 mice 
were isolated by collagenase (Sigma) digestion 
as previously described (Alonso-Magdalena 
et al. 2006). Islets were collected with a micro-
pipette one by one and were used immediately 
after isolation. Islets were washed twice with 
a buffer solution containing 120 mM NaCl, 
25 mM NaHCO3, 5 mM KCl, 2.5 mM 
CaCl2, 1 mM MgCl2, and 3 mM d-glucose 
(final pH of 7.35). Groups of five islets were 
then incubated in 1 mL of this buffer in the 
presence of 3, 7, or 16 mM glucose. After 
1 hr, the medium was collected, and insulin 
was meas  ured in duplicate samples by radio-
immuno  assay using a Coat-a-Count kit 
(Diagnostic Products Corp., Los Angeles, CA, 
USA). Protein concentration was measured by 
the Bradford dye method (Bradford 1976).
Recording [Ca2+]i (intracellular calcium 
concentrations). Isolated islets of Langerhans 
were loaded with 5 µM fura 2-acetoxy  methyl 
ester for at least 1 hr at room temperature. We 
obtained calcium records for the whole islet 
of Langerhans by imaging intra  cellular cal-
cium under an inverted epifluorescence micro-
scope (Axiovert 200; Carl Zeiss GmbH, Jena, 
Germany). Images were acquired every 2 sec 
with an extended Hamamatsu Digital Camera 
(model C4742-95; Hamamatsu Photonics, 
Barcelona, Spain) using a dual-filter wheel 
equipped with 340 and 380 nm, 10-nm 
bandpass filters. Data were acquired using 
AquaCosmos software from Hamamatsu.
Fluorescence changes are expressed as the ratio 
of fluorescence at 340 and 380 nm (F340/F380). 
Results were plotted and analyzed with use of 
commercially available software (SigmaPlot, 
version 8.0; SPSS Inc., Chicago, IL, USA).
Western blots. We conducted insulin sig-
naling experiments for Western blot analysis. 
Briefly, pregnant mice were fasted 4 hr and 
administered a single intraperitoneal injection 
of insulin (0.6 U/kg); tissues were harvested 
10 min later. Gastrocnemius muscles and liver 
were homogenized in ice-cold buffer [10% 
glycerol, 20 mM sodium pyrophosphate, 
150 mM NaCl, 50 mM HEPES (pH 7.5), 
1% NP-40, 20 mM β-glycerophosphate, 
10 mM sodium fluoride, 1 mM EDTA, 1 mM 
EGTA, 2 mM phenyl  methyl  sulfonyl fluoride, 
10 µg/mL aprotinin, 10 µg/mL leupeptin, 
2 mM sodium orthovanadate, 3 mM benz-
amidine (pH 7.4)] for 20 sec. Homogenates 
were rotated end over end for 1 hr at 4°C and 
subjected to centrifugation (14,000 × g for 
10 min) at 4°C. Protein content in lysates was 
measured by the Bradford method (Bradford 
1976). Muscle and liver lysates were adjusted to 
equal protein concentration, boiled in Laemmli 
buffer, and loaded on 7.5% gels. Membranes 
were blocked in Tris-buffered saline/Tween 
(TBST) buffer (10 mM Tris-base, 150 mM 
NaCl, 0.25% Tween 20) containing 5% low-
fat milk protein for 2 hr at room temperature. 
Membranes were then incubated with primary 
antibodies overnight at 4°C, washed with 
TBST buffer, and incubated with appropriate 
horse  radish peroxidase-conjugated secondary 
antibody (Bio-Rad, Richmond, CA, USA) for 
1 hr at room temperature.
We determined Akt phosphorylation by 
using an antibody against phospho-Akt [thre-
onine308 (Thr308); 1:1,000; Cell Signaling, 
Danvers, MA, USA]. An anti-Akt antibody was 
used to confirm equal loading and normalize 
samples. Protein bands were revealed using the 
Pierce ECL chemiluminescence kit (Amersham 
Biosciences, Barcelona, Spain). Intensity of the 
bands was quantified using Scion Image soft-
ware (Scion, Frederick, MD, USA).
Assessment of pancreatic β‑cell area. 
Pancreata were removed from F1 mice at 
the time of sacrifice (6 months of age) and 
fixed overnight in 4% paraformaldehyde. 
Subsequently, pancreatic tissue was embedded 
in paraffin, and 5-µm sections were prepared. 
After rehydra  tion and permeabilization (1% 
Triton X-100), sections were incubated with 
anti-insulin and anti-glucagon antibodies (both 
from Sigma) overnight at 4°C. Detection was Bisphenol A is diabetogenic
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performed with rhodamine- and fluorescein-
conjugated secondary antibodies (Jackson 
Immunoresearch, Suffolk, UK). For quantifi-
cation of β-cell area, sections were viewed at a 
magnification of 10×. We measured the cross-
sectional area of the islet and the total pancreatic 
area sing the ImageJ analysis program (National 
Institutes of Health, Bethesda, MD, USA). At 
least three sections, separated by 200 µm, were 
measured per animal. For quantification of the 
number of islets per area, only islets with more 
than five positive-stained cells were scored.
Analysis of bromodeoxyuridine (BrdU) 
incorporation. Mice (the same mice also 
used for assessment of pancreatic β-cell area) 
were given intra  peritoneal injections of BrdU 
(100 µg/g) 4 hr before sacrifice. Pancreatic 
tissue was collected, fixed, and processed as 
described above. After dehydration, sections 
were heated to 100°C in the presence of cit-
rate buffer (10 mM) for 5 min. Slides were 
then blocked by incubating for 30 min in 
0.1% bovine serum albumin and 5% normal 
goat serum in phosphate-buffered saline/0.2% 
TX-100. Samples were then incubated with 
antibodies for insulin (1:200, rabbit poly-
clonal; Santa Cruz Biotechnology, Madrid, 
Spain) and BrdU (1:200, mono  clonal; 
DAKO, Barcelona, Spain) overnight at 4°C. 
After incubation with secondary anti  bodies, 
sections were mounted using Fluorsave 
(Calbiochem, Madrid, Spain). Images were 
acquired from double-stained sections. BrdU-
positive nuclei were scored only in cells that 
were also positive for insulin. Quantification 
was done on at least three sections, separated 
by 200 µm, from each animal.
Statistical analysis. SigmaStat 3.1 software 
(Systat Software, Inc., Chicago, IL, USA) was 
used for all statistical analyses. To assess differ-
ences between treatment groups for each expo-
sure paradigm, we used one-way analy  sis of 
variance (ANOVA) followed by the Bonferroni 
post hoc test. Results in Figure 1C and D were 
analyzed by two-way ANOVA followed by the 
Fisher least significant difference test. When 
data did not pass the parametric test, we used 
ANOVA on ranks followed by Dunn’s test 
(noted in figure legends). Results were con-
sidered significant at p < 0.05. All results are 
expressed as mean ± SE
Results
BPA exposure during pregnancy: consequences 
for maternal glucose homeostasis. To exam-
ine the effects of BPA on maternal glucose 
metabo  lism, we treated pregnant mice with 
either vehicle [controls, F0-C] or BPA at doses 
of 10 µg/kg/day (F0-BPA10) or 100 µg/kg/day   
(F0-BPA100) on GD9–GD16. We then 
meas  ured glucose and insulin sensitivity and 
plasma metabolites on GD16–GD18. Across 
the groups, we matched animals for gestation 
day to minimize potential differences in the 
background levels of maternal hormones dur-
ing the last phase of pregnancy. 
Results of the IPGTT revealed that 
F0-BPA10 mice displayed glucose intolerance 
compared with F0-C mice (Figure 1A). The 
F0-BPA100 group displayed a tendency to 
glucose intolerance, yet the area under the 
curve (AUC), an index of glucose tolerance, 
was not significantly different than for vehicle-
treated animals (Figure 1A, inset). We per-
formed IPITTs to assess insulin sensitivity. 
In both F0-C and F0-BPA10 mice, insulin 
caused only a modest decrease in serum glu-
cose levels, reflecting the physiological insulin 
resistance that develops during late pregnancy. 
However, we observed a tendency to increased 
insulin sensitivity in F0-BPA100 mice, 
although this did not reach statistical signifi-
cance (Figure 1B).
Because BPA treatment during pregnancy 
led to altered glucose homeo  stasis, particu-
larly in the F0-BPA10 group, we next studied 
signaling pathways in liver and skeletal mus-
cle of pregnant mice that had received intra-
peritoneal injections of insulin. In liver from 
F0-C mice, insulin increased the phosphoryla-
tion of Akt compared with saline treatment 
(Figure 1C). In contrast, insulin stimulation 
actually decreased Akt phosphorylation in 
liver of F0-BPA10 mice, suggesting that BPA 
treatment impairs hepatic insulin signaling. 
In gastroc  nemius muscle (Figure 1D), insulin 
increased Akt phosphorylation in the F0-C 
group, whereas this response was completely 
blunted in the F0-BPA10 group, consistent 
with severe insulin resistance. These results 
demonstrate that the lowest dose of BPA had 
considerable effects on glucose homeo  stasis 
and enhanced insulin resistance in both liver 
and muscle from pregnant mice. Consistent 
with this, we detected hyper  insulinemia in 
both F0-BPA10 and F0-BPA100 mice rela  tive 
to F0-C mice (Table 1). F0-BPA100 mice also 
exhibited higher levels of plasma tri  glycerides 
Figure 1. BPA exposure during pregnancy on blood glucose homeostasis in F0 mice. (A) IPGTT performed 
in F0‑C (n = 11), F0‑BPA10 (n = 8), and F0‑BPA100 (n = 8); the inset shows mean total AUC in response to 
glucose load. (B) IPITT in F0‑C (n = 12), F0‑BPA10 (n = 9), and F0‑BPA100 (n = 7) mice. (C and D) Western 
blots (top) and analysis (bottom) of insulin‑stimulated Akt phosphorylation (Thr308; pAkt) in liver (C) and in 
gastrocnemius muscle (D); tissue for these experiments was collected 15 min after intraperitoneal injection 
of insulin (0.6 U/kg) or saline in F0‑C (n = 4) and F0‑BPA10 (n = 6) mice. Values for analysis are in arbitrary 
units (AU). Data are expressed as mean ± SE. 
*p < 0.05.
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Table 1. Plasma hormone and metabolite levels after 4 hr of fasting in pregnant mice on GD18 (n = 8–13 
mice/group).
End point F0-C F0-BPA10 F0-BPA100
Insulin (µg/L) 0.82 ± 0.13 1.13 ± 0.15* 1.99 ± 0.37**
Triglycerides (mg/mL) 1.07 ± 0.15 1.71 ± 0.25 2.04 ± 0.36*
Glycerol (mg/mL) 0.33 ± 0.04 0.55 ± 0.07 0.87 ± 0.15*
Leptin (ng/mL) 1.2 ± 0.15 1.35 ± 0.11 2.52 ± 0.31*
*p < 0.05, and **p < 0.005, compared with F0‑C, by one‑way ANOVA followed by Bonferroni. Alonso-Magdalena et al.
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and glycerol and increased plasma leptin com-
pared with F0-C mice (Table 1).
BPA exposure during pregnancy: conse‑
quences for mothers later in life. To determine 
whether BPA exposure during pregnancy is 
detrimental to glucose metabolism in females 
after parturition, we treated pregnant mice 
as described above and monitored metabolic 
parameters in these animals for several months 
post  partum. Three months after delivery, 
BPA-treated animals showed an increase of 
body weight that was more pronounced in the 
F0-BPA100 group [see Supplemental Material, 
Figure 1A (doi:10.1289/ehp.1001993)]. At 
this point of evaluation, we observed no sta-
tistically significant differences in insulin sen-
sitivity in F0-BPA100 mice (see Supplemental 
Material, Figure 1B).
Four months after delivery, the increased 
body weight associated with BPA expo-
sure persisted in the F0 mice (Figure 2A); 
no differences in food intake were meas  ured 
during a 6-day evaluation [see Supplemental 
Material,  Figure  1C  (doi:10.1289/
ehp.1001993)]. When we performed the 
IPITT, the glucose-lowering effects of insulin 
were attenuated in F0-BPA100 compared 
with F0-C mice (Figure 2B). Consistent 
with this, we observed that glucose toler-
ance was clearly altered in F0-BPA100 mice 
(Figure 2C). Accordingly, in mice fasted 
4 hr, plasma insulin levels were 2.2 times 
higher in the F0-BPA100 mice than in con-
trols (Table 2), whereas glucose levels did 
not differ. These observations reinforced the 
idea that F0-BPA100 animals develop insu-
lin resistance. Moreover, the higher plasma 
insulin levels were accompanied by increased 
plasma leptin, tri  glyceride, and glycerol lev-
els relative to controls (Table 2). However, 
in the case of F0-BPA10, we observed no 
differences in IPITT and IPGTT results 
(Figure 2B,C), and only triglyceride levels 
were statistically different from those in con-
trol animals (Table 2). Nevertheless, plasma 
insulin, glycerol, and leptin levels were also 
increased, although the increases were not 
statistically significant (Table 2). Collectively, 
these results suggest that exposure to a BPA 
dose of 100 µg/kg/day during pregnancy 
has persistent metabolic consequences that, 
with time, lead to insulin resistance and dys-
regulated nutrient metabolism.
BPA exposure during pregnancy: fetal 
programming of type 2 diabetes in adult off‑
spring. To test whether BPA exposure in utero 
predisposes for future development of meta-
bolic abnormalities, we studied three groups 
of animals: offspring from F0-C mothers 
(F1-C), offspring from F0-BPA10 mothers 
(F1-BPA10), and offspring from F0-BPA100 
mothers (F1-BPA100). Note that these off-
spring received no direct treatment with BPA, 
but their mothers were treated GD9–GD16.
F1-BPA10 mice were 3% heavier than 
F1-C mice at birth and 7% heavier at wean-
ing (21 days postpartum). In contrast, body 
weight in the F1-BPA100 group was 4.5% 
lower than that of F1-C controls at birth, and 
Figure 2. Analysis of glucose and insulin sensitiv‑
ity in F0‑C, F0‑BPA10, and F0‑BPA100 female mice 
(F0) 4 months after delivery. (A) Mean body weight. 
(B) IPITT. (C) IPGTT in the same mothers as in B; 
the inset represents the AUC. Data are expressed 
as mean ± SE (n = 6/group).
*p < 0.05 for F0‑BPA100 mice compared with F0‑C. 
50
40
30
20
10
0
110
100
90
80
70
60
50
40
30
300
250
200
150
100
50
FO-C FO-BPA10
*
FO-BPA100
W
e
i
g
h
t
 
(
g
)
P
e
r
c
e
n
t
 
g
l
u
c
o
s
e
G
l
u
c
o
s
e
 
(
m
g
/
d
L
)
01 0
*
* *
*
* *
20
Time (min)
30 40 50 60 70
02 04 0
Time (min)
60 80 100 120 140
FO-C
FO-BPA10
FO-BPA100
200
150
100
50
0
A
U
C
 
(
m
g
/
d
L
.
 
m
i
n
)
C1 0
*
100
Figure 3. Body weight of F1‑C, F1‑BPA10, and F1‑BPA100 mice. Mean body weight (A) and percentage of 
control weight (B) from birth to weaning for males and females combined. (C, D) Mean body weight from 
weaning to adulthood (22 through 180 days of age) for males (C) and females (D). n = 25–60 animals/group; 
some SEs are not visible because of their low values. 
*p < 0.05 for F1‑BPA10 compared with F1‑C. #p < 0.05 for F1‑BPA100 compared with F1‑C.
F1-C
F1-BPA10
F1-BPA100
00 55 10
Time (days)
W
e
i
g
h
t
 
(
g
)
W
e
i
g
h
t
 
(
g
)
W
e
i
g
h
t
 
(
g
)
P
e
r
c
e
n
t
 
c
o
n
t
r
o
l
 
w
e
i
g
h
t
 
Time (days)
Time (weeks) Time (weeks)
10 15
*
*
*
*
#
#
#
#
*
15 20 20 25
20
18
16
14
12
10
8
6
4
2
0
55
50
45
40
35
30
25
20
15
10
45
40
35
30
25
20
15
10
115
110
105
100
95
90
85
4 6 81 01 1 13
Males Females
14 16 23 25 4 6
* *
* * *
*
81 01 1 13 14 16 23 25
Table 2. Plasma hormone and metabolite levels after 4 hr fasting in F0 mice 4 months after delivery (n = 6 
mice/group).
End point F0-C F0-BPA10 F0-BPA100
Insulin (µg/L) 0.94 ± 0.20 1.61 ± 0.17 2.08 ± 0.39*
Triglycerides (mg/mL) 0.44 ± 0.07 1.22 ± 0.29# 1.97 ± 0.30#
Glycerol (mg/mL) 0.27 ± 0.03 0.66 ± 0.17 0.94 ± 0.19*
Leptin (ng/mL) 2.70 ± 0.59 5.33 ± 1.12 6.05 ± 1.06*
*p < 0.05, compared with F0‑C, by one‑way ANOVA followed by Bonferroni. #p < 0.05, compared with F0‑C, by one‑way 
ANOVA followed by Holm‑Sidak. Bisphenol A is diabetogenic
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the relative difference persisted until wean-
ing (Figure 3A,B). In male offspring, body 
weight was comparable among experimental 
groups from weaning through 6 months of 
age (Figure 3C). In female offspring body 
weight was also comparable among groups in 
the post  natal period, but at 3 months of age 
F1-BPA10 and F1-BPA100 mice weighed 3% 
and 2.5% less, respectively, than did F1-C 
controls (Figure 3D).
When mice were 3 months of age, we per-
formed IPITT to evaluate insulin sensitivity 
of the offspring. Insulin sensitivity was slightly 
decreased in F1-BPA10 male offspring com-
pared with controls but not in F1-BPA100 
offspring. Nevertheless, differences were not sta-
tistically significant [see Supplemental Material, 
Figure 2A (doi:10.1289/ehp.1001993)]. No 
differences were detected in female offspring 
(see Supplemental Material, Figure 2B).
In 6-month-old male mice, insulin sen-
sitivity was clearly impaired in F1-BPA10 
animals, as shown in Figure 4A, yet insu-
lin sensitivity was normal in F1-BPA100 
males. Glucose tolerance was altered in both 
F1-BPA10 and F1-BPA100 males: The AUC 
was significantly increased in F1-BPA10 and 
non  significantly increased in F1-BPA100 
mice relative to F1-C controls (Figure 4B, 
inset). In 6-month-old female offspring, we 
found no differences in insulin sensitivity or 
glucose tolerance [see Supplemental Material, 
Figure 2C,D (doi:10.1289/ehp.1001993)]. 
Therefore, we performed subsequent studies 
only with male animals.
Serum insulin and glycerol levels were 
higher in F1-BPA10 male mice compared with 
F1-C males, but leptin levels were comparable 
(Table 3). Interestingly, in F1-BPA100 mice, 
only glycerol levels were significantly increased 
relative to controls. To relate these observa-
tions with alterations in the endocrine pan-
creas, we studied glucose-stimulated insulin 
secretion 15 min after a glucose load in vivo 
and ex vivo. Glucose-stimulated insulin secre-
tion was doubled in F1-BPA10 mice relative to 
F1-C males but was comparable in F1-BPA100 
mice (Figure 5A). After ex vivo exposure to 
high glucose concentrations (16 mM), islets 
from F1-BPA10 mice secreted 1.53 times 
more insulin than did islets from control 
mice, whereas islets from F1-BPA100 mice 
secreted slightly less insulin than did controls, 
although the difference was not statistically sig-
nificant (Figure 5B). Enhanced insulin secre-
tion in F1-BPA10 mice was accompanied by 
a greater increase in global intracellular Ca2+ 
entry after glucose stimulation. However, in 
the F1-BPA100 group, the increase in global 
Ca2+ entry was slightly less than the response 
observed in controls (not statistically sig-
nificant; Figure 5C,D). We next studied 
whether pancreatic β-cell mass was altered in 
BPA-treated male mice. Although we found 
no change in β-cell area among the groups 
(Figure 5E), BrdU incorporation into β cells, a 
marker of proliferation, was markedly reduced 
in both F1-BPA10 and F1-BPA100 males   
relative to F1-C mice (Figure 5F).
Discussion
In the present study, we have demonstrated 
that exposure to low doses of BPA during 
critical periods of life has adverse effects on 
glucose homeo  stasis and insulin sensitivity. 
When pregnant mice were treated with BPA 
on GD9–GD16, they developed glucose intol-
erance and elevated levels of plasma insulin, 
triglycerides, glycerol, and leptin compared 
with control pregnant mice. Interestingly, this 
brief exposure to BPA had long-term meta-
bolic consequences for both the mothers and 
their male offspring.
BPA exposure in mothers: consequences 
for glucose homeostasis during pregnancy. 
Maternal adaptation to pregnancy is mediated 
mainly by placental hormones, such as prolac-
tin, placental lactogens, and steroid hormones, 
including estrogens (Nadal et al. 2009b). 
Estrogen signaling is emerging as a key path-
way in glucose and lipid metabo  lism and may 
play an important role in the insulin resis-
tance that occurs during pregnancy (Gonzalez 
et al. 2003). In the pancreas, estrogen recep-
tors (ERs) are important in the regulation of 
insulin bio  synthesis and release, a process that 
appears to counter  act the increased insulin 
resistance associated with pregnancy (Nadal 
et al. 2009b). BPA is a xeno  estrogen, and 
its estrogenic effect alters pancreatic β-cell 
function and induces glucose intolerance 
and insulin resistance in male mice (Alonso-
Magdalena et al. 2006). Moreover, its effect in 
β cells is direct and occurs via ERα (Alonso-
Magdalena et al. 2008). In addition, BPA 
binding to extra  nuclear ERα alters prolactin 
secretion (Wozniak et al. 2005). Therefore, 
alterations of estrogen signaling by BPA treat-
ment during pregnancy would be expected 
to produce deleterious effects on the adapta-
tion of the endocrine pancreas, pituitary, and 
other peripheral tissues.
Results of the present study indicate 
that, compared with F0-C mice, F0-BPA10 
mice had impaired glucose tolerance, 
slightly increased fasting plasma insulin lev-
els (1.38 times higher than in controls), and 
reduced insulin sensitivity in skeletal muscle 
and liver (as evidenced by the inability of 
insulin to promote phosphorylation of Akt 
at Thr308 in these tissues) (Alessi et al. 1996). 
Thus, the reduction in glucose tolerance 
observed in F0-BPA10 mice compared with 
controls may reflect an inability to increase 
insulin levels enough to compensate for the 
observed increase in insulin resistance. In 
contrast, higher fasting plasma insulin lev-
els in F0-BPA100 mice (double the mean 
concentration in controls) may have par-
tially compensated for the relative increase 
in insulin resistance that we also observed 
in F0-BPA100 mice, and may explain why 
F0-BPA100 mice tolerated a glucose chal-
lenge better than did F0-BPA10 mice. In 
addition, fasting plasma leptin levels were 
2.1 times higher in F0-BPA100 mice than 
in F0-C mice. A major function of leptin is 
regu  la  tion of glucose metabolism and insulin 
sensitivity in muscle, liver, and endocrine pan-
creas (Tudurí et al. 2009; Wang et al. 2010). 
Figure 4. Blood glucose homeostasis in F1‑C, F1‑BPA10, and F1‑BPA100 mice at 6 months of age shown by 
(A) IPITT and (B) IPGTT performed in the same group of animals. The inset in B represents the mean total 
glucose AUC. Data are expressed as mean ± SE (n = 8).
*p < 0.05 for F1‑BPA10 and F1‑BPA100 mice compared with F1‑C. ##p = 0.05. 
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Table 3. Plasma hormone and metabolite levels after 4 hr of fasting in male offspring at 6 months of age 
(n = 6–13 mice/group).
End point F1-C F1-BPA10 F1-BPA100
Insulin (µg/L) 0.85 ± 0.13 1.73 ± 0.25* 1.40 ± 0.18
Triglycerides (mg/mL) 0.84 ± 0.16 1.41 ± 0.03 1.25 ± 0.09
Glycerol (mg/mL) 0.18 ± 0.02 0.27 ± 0.02# 0.24 ± 0.02#
Leptin (ng/mL) 1.69 ± 0.42 1.78 ± 0.47 1.85 ± 0.44
*p < 0.05, compared with F1‑C mice, by one‑way ANOVA followed by Bonferroni. #p < 0.05, compared with F1‑C mice, by 
one‑way ANOVA followed by Holm‑Sidak. Alonso-Magdalena et al.
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Leptin levels are increased during pregnancy, 
and leptin receptors are present in maternal 
tissue, placenta, and fetal tissue (Sagawa et al. 
2002). Therefore, increased levels of leptin 
may affect energy metabolism in mothers as 
well as fetal growth. It will be of interest to 
determine whether BPA directly regulates lep-
tin release from adipocytes, as is the case of 
adiponectin secretion (Hugo et al. 2008), or 
whether the observed hyper  leptinemia is a 
consequence of the altered metabolic state of 
these animals.
BPA treatment during pregnancy affects 
mother’s glucose metabolism later in life. 
Experimental and observational data sug-
gest that gestational diabetes may increase a 
mother’s risk for obesity and type 2 diabetes 
later in life (Boloker et al. 2002; Reece et al. 
2009). F0-BPA10 mice weighed more (not 
significant) and had higher plasma tri  glyceride 
levels 4 months after delivery than controls. 
It is important to note that a BPA dose   
of 10 µg/kg/day is 5 times lower than the dose 
considered completely safe during a lifetime 
by the U.S. EPA (2010). The effects observed 
in F0-BPA100 mice, only twice the level 
considered safe during lifetime by U.S. EPA   
(50 µg/kg/day), were even more striking. With 
the higher dose, pregnant mice demonstrated 
increased insulin resistance, decreased glu-
cose tolerance, and significantly higher fasting 
plasma insulin, leptin, tri  glyceride, and glycerol 
levels than F0-C mice. In humans, these meta-
bolic alterations are associated with an increased 
risk of type 2 diabetes and cardio  vascular dis-
ease (Kahn et al. 2006). Interestingly, increased 
insulin resistance in F0-BPA100 mice was not 
evident 3 months after delivery but was evi-
dent 4 months after delivery, which suggests 
that insulin resistance resolved after parturition 
but was triggered several months later by a yet 
unknown mechanism.
Effects of EDCs, including those of 
BPA, are usually classified as “activational” 
and “organizational.” “Activational” refers 
to effects resulting from adult exposure, and 
they are generally considered to be revers-
ible. “Organizational” refers to effects result-
ing from peri  natal exposure, and it is well 
accepted that these effects can persist even in 
the absence of subsequent reexposure (Richter 
et al. 2007). In the present study, we observed 
an effect of BPA in adults that appeared dur-
ing gestational exposure, disappeared after 
labor, and reappeared later in life. Thus, these 
results challenge the long-standing assump-
tion that effects of exposure to endocrine 
disruptors during adulthood are reversible 
after exposure ceases. The mechanistic basis of 
these alterations is not yet known, although 
it is plausible that epigenetic modifications 
of maternal tissues may influence metabolism 
later in life and, perhaps, during subsequent 
pregnancies.
BPA treatment during pregnancy: impli‑
cations for offspring metabolism. It is well 
known that conditions experienced in utero 
can have lifelong effects on health, the “fetal 
plasticity” theory (Barker 1998; Gilbert and 
Epel 2009). Experimental and epidemiologi-
cal studies in rodents and humans suggest 
that high or low birth weight is a risk factor of 
type 2 diabetes later in life (Gilbert and Epel 
2009). Mice with low birth weight from mal-
nourished mothers present glucose intolerance 
and β-cell failure during adulthood (Jimenez-
Chillaron et al. 2005). In utero exposure to 
EDCs, such as diethylstilbestrol (DES), pro-
vokes various diseases in offspring during 
adulthood (McLachlan et al. 2001). Although 
information related to EDC-induced meta-
bolic syndrome is sparse, it is known that 
uterine exposure to DES in mice induces high 
birth weight and obesity in adult offspring 
(Newbold et al. 2008, 2009). Moreover, 
in utero exposure to low doses (25 µg/kg/day) 
of BPA in rats is associated with high birth 
weight (Rubin and Soto 2009).
Our results demonstrate that exposure 
during pregnancy to 10 µg/kg/day BPA was 
associated with higher birth weight. This may 
have reflected effects on the metabolic state of 
the mothers (F0-BPA10)—primarily reduced 
glucose tolerance and increased plasma insulin 
levels—which are factors that may influence 
fetal growth (Reece et al. 2009). Offspring 
(F1-BPA10) also demonstrated reduced glu-
cose tolerance, increased insulin resistance, and 
Figure 5. Pancreatic islet function in male F1‑C, F1‑BPA10, and F1‑BPA100 mice. In vivo plasma insulin 
levels 15 min after a glucose load (2 g/kg; A) and ex vivo glucose‑induced insulin secretion from isolated 
islets (3, 7, and 16 mM glucose; B); n = 8–10 animals/group. (C) [Ca2+]i response of a representative islet of 
Langerhans in the presence of 3, 7 and 16 mM glucose applied for 10, 10, and 15 min, respectively (n = 10/
group). (D) AUC for traces in C. (E) Measurement of β‑cell area (area occupied by insulin‑positive cells 
expressed as a percentage of the total area). (F) Quantification of BrdU incorporation in insulin‑positive 
cells. Data are expressed as mean ± SE. 
*p < 0.05 compared with F1‑C. **p < 0.005.
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higher levels of plasma insulin and glycerol 
(an indicator of high free fatty acids). In addi-
tion, β cells from F1-BPA10 mice were more 
sensitive to extra  cellular glucose, both in vivo 
and ex vivo. This enhanced secretion of insulin 
may represent a homeo  static mechanism to 
compensate for an increase in peripheral insu-
lin resistance. However, the incorporation of 
BrdU, which we used to assess β-cell prolifera-
tion, was significantly reduced in both groups 
of BPA-exposed offspring compared with F1-C 
mice. This seeming contradiction between pre-
served β-cell mass and impaired BrdU incor-
poration might be explained by the effects of 
BPA on β-cell turnover. Although adult β cells 
expand during adulthood to match peripheral 
demands for insulin, recent studies have shown 
that in fact β cells from aged mice reside in a 
mostly quiescent state and display a very low 
rate of turnover (Teta et al. 2005, 2007). Thus, 
it is plausible that in utero exposure to BPA 
alters cell-cycle machinery without provok-
ing apoptosis of β cells, and given that insulin 
secretion is enhanced, diabetes can be avoided 
in these animals until the increased demand 
for insulin reaches a point where expansion of 
β cells is also required to compensate for insu-
lin resistance.
Notably, the metabolic phenotype of 
F1-BPA100 is quite different from that of 
the F1-BPA10 group. F1-BPA100 mice had 
lower birth weights than the F1-C group. 
Because F0-BPA100 mice presented milder 
glucose intolerance and higher levels of lep-
tin than F0-BPA10 mice, this may influence 
birth weight and therefore glucose homeo-
stasis of offspring. In addition, F1-BPA100 
mice presented milder glucose intolerance than 
F1-BPA10 mice but normal insulin sensitivity 
and plasma insulin levels that were not statisti-
cally different from controls. When we ana-
lyzed in vivo pancreatic β-cell function, we 
found that the insulin response to an intra-
peritoneal injection of glucose was reduced in 
F1-BPA100 mice relative to controls. Ex vivo 
experiments with isolated islets indicate that 
glucose-induced Ca2+ signals and insulin release 
were only slightly diminished with respect to 
controls. Therefore, F1-BPA100 animals pre-
sented glucose intolerance likely due to liver 
insulin resistance rather than to alterations in 
the β-cell stimulus–secretion coupling.
Only male offspring had altered glucose 
tolerance and insulin resistance; age- and 
treatment-matched female offspring displayed 
normal metabolic parameters. Females are pro-
tected against insulin resistance more than are 
males, in part because the presence of estro-
gens—within the physiological range—protect 
against diabetes in mice (Liu and Mauvais-
Jarvis 2010; Louet and Mauvais-Jarvis et al. 
2004). Moreover, at 3 months of age, neither 
males nor females presented insulin resistance 
or glucose intolerance. In a study of glucose 
tolerance, Ryan et al. (2010) described similar 
results until 15 weeks of age, concluding that 
peri  natal exposure to BPA (0.25 µg/kg/day) 
did not affect glucose homeo  stasis in adult 
mice. However, in the present study, although 
the BPA treatment protocol was different, 
metabolic alterations did not appear until later 
in adulthood (6 months of age).
The “developmental” or “fetal” origin of 
adult disease hypothesis states that environ-
mental factors act early in life to program the 
risks of developing chronic diseases in adult 
life. In our model, metabolic effects observed 
in mice pre  natally exposed to BPA may be due 
to two factors: abnormal hormonal environ-
ment and altered glucose metabolism. Whether 
the effects we observed in the offspring are due 
to a direct effect of BPA on the fetus or because 
the fetus is exposed to an altered maternal 
metabolism, or the combination of both fac-
tors, remains unknown. Nevertheless, the latter 
is the most plausible situation because BPA 
crosses the placenta and because glucose toler-
ance, insulin, and leptin signaling during ges-
tation are important for fetal growth. Indeed, 
maternal metabolism is important because 
the different impaired glucose tolerance and 
blood parameters observed in F0-BPA10 and 
F0-BPA100 mice may explain, at least in part, 
the different metabolic abnormalities displayed 
subsequently in their offspring (F1-BPA10 and 
F1-BPA100 mice, respectively).
In any case, the results of the present study 
suggest that the endocrine disruptor BPA 
should be evaluated as a possible risk factor 
for gestational diabetes, type 2 diabetes, and 
cardio  vascular disease associated with meta-
bolic syndrome. Moreover, our findings in 
mice suggest that fetal exposure to BPA may 
predispose males to type 2 diabetes during 
adulthood.
co r r e c t i o n
In the manuscript originally published 
online, the the units given in the tables for 
leptin levels (mg/mL) should have been 
ng/mL. They have been corrected here.
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